Physician profile
Marvin C Schlecte, JR.
NPI 1134188774
$2,775.81
in general payments reported to CMS, 2019-2025
15 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.16 · 2020: $24.51 · 2021: $119 · 2022: $222 · 2023: $1,565 · 2024: $348 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199 · Travel and Lodging: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.94 |
| Travel and Lodging | $1,128.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,372.99 | 2023 | Cirrus Hd-Oct, Artevo 800, Visumax |
| Abbvie INC. | $405.80 | 2022-2025 | Lumigan, Alphagan P |
| Alcon Vision LLC | $240.72 | 2019-2025 | Argos, Clareon, Eysuvis |
| Dompe US, INC. | $184.09 | 2024-2025 | Oxervate |
| Allergan, INC. | $127.95 | 2021-2022 | |
| Biotissue Holdings INC. | $96.82 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $74.53 | 2022-2024 | Vyzulta, Miebo, Xiidra |
| Astellas Pharma US INC | $52.67 | 2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $51.85 | 2020-2021 | |
| Shire North American Group INC | $46.87 | 2019 | |
| Oyster Point Pharma, INC. | $41.88 | 2022-2025 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $23.42 | 2024 | Iyuzeh |
| Amgen INC. | $23.10 | 2024 | Tepezza |
| Kala Pharmaceuticals, INC. | $18.98 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Schlecte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.